JP7554263B2 - アルカリ金属塩、薬学的製剤、アルカリ金属塩の使用、及びプロセス - Google Patents

アルカリ金属塩、薬学的製剤、アルカリ金属塩の使用、及びプロセス Download PDF

Info

Publication number
JP7554263B2
JP7554263B2 JP2022523275A JP2022523275A JP7554263B2 JP 7554263 B2 JP7554263 B2 JP 7554263B2 JP 2022523275 A JP2022523275 A JP 2022523275A JP 2022523275 A JP2022523275 A JP 2022523275A JP 7554263 B2 JP7554263 B2 JP 7554263B2
Authority
JP
Japan
Prior art keywords
alkali metal
metal salt
pharmaceutical formulation
copolymer
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553268A5 (enExample
JP2022553268A (ja
Inventor
トーマス エドランド
ヤコブ ウェストマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagenon AB
Original Assignee
Betagenon AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon AB filed Critical Betagenon AB
Publication of JP2022553268A publication Critical patent/JP2022553268A/ja
Publication of JP2022553268A5 publication Critical patent/JP2022553268A5/ja
Priority to JP2024153951A priority Critical patent/JP7771316B2/ja
Application granted granted Critical
Publication of JP7554263B2 publication Critical patent/JP7554263B2/ja
Priority to JP2025186783A priority patent/JP2026027357A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
JP2022523275A 2019-10-18 2020-10-16 アルカリ金属塩、薬学的製剤、アルカリ金属塩の使用、及びプロセス Active JP7554263B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024153951A JP7771316B2 (ja) 2019-10-18 2024-09-06 組成物
JP2025186783A JP2026027357A (ja) 2019-10-18 2025-11-05 組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201915094A GB201915094D0 (en) 2019-10-18 2019-10-18 New formulations
GB1915094.5 2019-10-18
PCT/GB2020/052618 WO2021074646A1 (en) 2019-10-18 2020-10-16 New formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024153951A Division JP7771316B2 (ja) 2019-10-18 2024-09-06 組成物

Publications (3)

Publication Number Publication Date
JP2022553268A JP2022553268A (ja) 2022-12-22
JP2022553268A5 JP2022553268A5 (enExample) 2023-10-24
JP7554263B2 true JP7554263B2 (ja) 2024-09-19

Family

ID=68728312

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022523275A Active JP7554263B2 (ja) 2019-10-18 2020-10-16 アルカリ金属塩、薬学的製剤、アルカリ金属塩の使用、及びプロセス
JP2024153951A Active JP7771316B2 (ja) 2019-10-18 2024-09-06 組成物
JP2025186783A Pending JP2026027357A (ja) 2019-10-18 2025-11-05 組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024153951A Active JP7771316B2 (ja) 2019-10-18 2024-09-06 組成物
JP2025186783A Pending JP2026027357A (ja) 2019-10-18 2025-11-05 組成物

Country Status (16)

Country Link
US (1) US20230096218A1 (enExample)
EP (2) EP4045038B1 (enExample)
JP (3) JP7554263B2 (enExample)
KR (1) KR20220084379A (enExample)
CN (2) CN119112886A (enExample)
AU (1) AU2020366142A1 (enExample)
CA (1) CA3154915A1 (enExample)
DK (1) DK4045038T3 (enExample)
ES (1) ES2977279T3 (enExample)
FI (1) FI4045038T3 (enExample)
GB (1) GB201915094D0 (enExample)
HU (1) HUE066075T2 (enExample)
MX (2) MX2022004615A (enExample)
PL (1) PL4045038T3 (enExample)
PT (1) PT4045038T (enExample)
WO (1) WO2021074646A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
WO2025017193A1 (en) * 2023-07-20 2025-01-23 Betagenon Ab Methods of treating cardiomyopathy induced by metabolic inflexibility
WO2025017194A1 (en) * 2023-07-20 2025-01-23 Betagenon Ab Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532708A (ja) 2000-05-11 2003-11-05 コンセホ・スペリオル・インヴェスティガシオンズ・シエンティフィカス グリコーゲンシンターゼキナーゼｇｓｋ−３の複素環インヒビター
WO2006045581A1 (en) 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
JP2012532854A (ja) 2009-07-08 2012-12-20 バルティック バイオ アーベー 医薬として有用な化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
WO2013108026A1 (en) * 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
AU2018448511B2 (en) * 2018-11-05 2025-07-03 Betagenon Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532708A (ja) 2000-05-11 2003-11-05 コンセホ・スペリオル・インヴェスティガシオンズ・シエンティフィカス グリコーゲンシンターゼキナーゼｇｓｋ−３の複素環インヒビター
WO2006045581A1 (en) 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
JP2012532854A (ja) 2009-07-08 2012-12-20 バルティック バイオ アーベー 医薬として有用な化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
四ッ柳 智久 他，製剤学 改訂第４版，株式会社南江堂，2003年，pp. 91-95, 106, 112, 174-175

Also Published As

Publication number Publication date
CA3154915A1 (en) 2021-04-22
US20230096218A1 (en) 2023-03-30
HUE066075T2 (hu) 2024-07-28
EP4316470B1 (en) 2026-04-29
EP4045038A1 (en) 2022-08-24
CN114630824B (zh) 2024-09-24
EP4045038B1 (en) 2023-12-06
CN119112886A (zh) 2024-12-13
MX2025003950A (es) 2025-08-01
FI4045038T3 (fi) 2024-03-13
AU2020366142A1 (en) 2022-06-02
JP2022553268A (ja) 2022-12-22
PL4045038T3 (pl) 2024-06-24
WO2021074646A1 (en) 2021-04-22
MX2022004615A (es) 2022-07-11
JP2024174965A (ja) 2024-12-17
JP7771316B2 (ja) 2025-11-17
PT4045038T (pt) 2024-03-11
ES2977279T3 (es) 2024-08-21
CN114630824A (zh) 2022-06-14
GB201915094D0 (en) 2019-12-04
JP2026027357A (ja) 2026-02-18
KR20220084379A (ko) 2022-06-21
DK4045038T3 (en) 2024-03-18
EP4316470A3 (en) 2024-02-28
EP4316470A2 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
JP7771316B2 (ja) 組成物
EP3302565B1 (en) Solid dosage forms of palbociclib
US20250289791A1 (en) Formulations
CN1642526A (zh) 碱性金属添加剂稳定的阿托伐他汀制剂
JP7231255B2 (ja) 改善されたブロモクリプチン製剤
WO2008072534A1 (ja) マンニトール又は乳糖を含有する固形製剤
EP4410793A1 (en) Solid composition of glp-1 receptor agonist
US20240082222A1 (en) 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine
WO2021009505A1 (en) New formulations
US20130237550A1 (en) Arylvinylazacycloalkane compounds for constipation
CN117295492A (zh) 多个他喹莫德粒子及其用途
WO2021009504A1 (en) New formulations
EP4410278A1 (en) Pharmaceutical composition comprising enavogliflozin
KR101476096B1 (ko) 용해도가 향상된 쎄레콕시브의 약제학적 조성물
WO1999020277A1 (en) Rapidly soluble drug composition
HK40063384A (en) Solid dosage forms of palbociclib
HK40107035A (en) A plurality of tasquinimod particles and use thereof
HK40107035B (en) A plurality of tasquinimod particles and use thereof
HK40018807B (en) Abiraterone acetate formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231016

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240906

R150 Certificate of patent or registration of utility model

Ref document number: 7554263

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150